<DOC>
	<DOCNO>NCT00975325</DOCNO>
	<brief_summary>- Type : Bioequivalence study male healthy volunteer , therapeutical indication ( erectile disfunction ) study - Products , dosage , route administration : - Test 1 : Yohimbin `` Spiegel '' ® ( Desma GmbH , Germany ) , tablet contain 5 mg yohimbine hydrochloride , oral administration - Reference : Yocon-Glenwood® ( Glenwood GmbH , Germany ) , tablet contain 5 mg yohimbine hydrochloride , oral administration - Duration treatment : 2 single-dose administration 5 mg yohimbine hydrochloride fast condition separate wash-out period least one week i.e . 6 treatment free day administration</brief_summary>
	<brief_title>Bioequivalence Study Comparing Two Test Products With One Reference Product , All Containing 5 mg Yohimbine</brief_title>
	<detailed_description>Study objectives Primary Objectives : - Characterisation relative bioavailability Test 1 comparison Reference single dose administration fast condition - Assessment bioequivalence Test 1 vs. Reference single dose administration fast condition , determine use area concentration time curve AUC0-tlast maximal concentration Cmax obtain yohimbine Secondary Objective : - Descriptive characterisation safety tolerability investigational product study population - Descriptive characterisation blood pressure pulse rate around Cmax investigational product study population Analytical methodology : Yohimbine plasma sample analyse use validated HPLC-MS/MS ; intend LLOQ yohimbine 0.5 ng/ml</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Yohimbine</mesh_term>
	<criteria>Sex : male Ethnic origin : Caucasian Age : 18 55 year , inclusive Bodymass index1 ( BMI ) : ≥ 19 kg/m² ≤ 27 kg/m² Good state health Nonsmoker exsmoker least 1 month Written inform consent , inform benefit potential risk trial , well detail insurance take cover subject participate study Safety concern : 1 . Existing cardiac haematological disease and/or pathological finding , might interfere safety , tolerability , absorption and/or pharmacokinetics active ingredient 2 . Existing hepatic and/or renal disease and/or pathological finding , might interfere safety , tolerability , absorption and/or pharmacokinetics active ingredient 3 . Existing gastrointestinal disease and/or pathological finding , might interfere safety , tolerability , absorption and/or pharmacokinetics active ingredient 4 . History relevant CNS and/or psychiatric disorder and/or currently treat CNS and/or psychiatric disorder 5 . Pathological ECG ( 12 standard lead ) might interfere safety active ingredient 6 . Known allergic reaction active ingredient use constituent pharmaceutical preparation 7 . Subjects severe allergy multiple drug allergy 8 . Systolic blood pressure &lt; 100/ &gt; 140 mmHg 9 . Diastolic blood pressure &lt; 60/ &gt; 90 mmHg 10 . Pulse rate &lt; 45/ &gt; 110 bpm 11 . Laboratory value normal range unless deviation normal judge relevant study investigator 12 . Positive antiHIVtest , HBsAGtest antiHCVtest 13 . History glaucoma Lack suitability trial 14 . Subjects exhibit extreme genetic polymorphism CYP 2D6 `` Poor Ultrarapid metabolizer '' 15 . Acute chronic disease could affect absorption metabolism 16 . History current drug alcohol dependence 17 . Regular intake alcoholic food beverage ≥ 40 g pure ethanol male per day 18 . Subjects diet could affect pharmacokinetics active ingredient 19 . Regular intake caffeine contain food beverage ≥ 500 mg per day 20 . Blood donation blood loss 400 ml within last two month prior individual enrolment subject 21 . Participation clinical trial last two month prior individual enrolment subject 22 . Regular treatment systemically available medication ( except continuous usual replacement therapy e.g . Lthyroxine ) within two week prior first administration study medication 23 . Intake yohimbine reason ( e.g . fat burning , weight reduction , muscle improvement , post operative care and/or therapy erectile dysfunction ) within two week prior first administration study medication 24 . Subjects , report frequent occurrence migraine attack Administrative reason 25 . Subjects suspect know follow instruction 26 . Subjects unable understand write verbal instruction , particular regard risk inconvenience expose participation study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Bioequivalency</keyword>
</DOC>